诺诚健华越来越有biopharma的模样了。这家成立于2015年创新药企，正以持续高光的表现献礼十周年。8月19日晚，诺诚健华发布2025年中期业绩报告，拳头产品奥布替尼实现了6.4亿元的收入，同比增长53%，助推公司上半年收入飙涨73%，达到7.3亿元。与此同时，公司当期亏损大幅缩窄87%，降至不到3600万元。目前来看，诺诚健华不断兑现全年预期，向着年度目标大踏步前进。站在十周年的新起点，...
Source Link诺诚健华越来越有biopharma的模样了。这家成立于2015年创新药企，正以持续高光的表现献礼十周年。8月19日晚，诺诚健华发布2025年中期业绩报告，拳头产品奥布替尼实现了6.4亿元的收入，同比增长53%，助推公司上半年收入飙涨73%，达到7.3亿元。与此同时，公司当期亏损大幅缩窄87%，降至不到3600万元。目前来看，诺诚健华不断兑现全年预期，向着年度目标大踏步前进。站在十周年的新起点，...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.